论文部分内容阅读
目的观察乳腺癌特异基因BCSG1在三阴乳腺癌新辅助化疗前后分子和蛋白水平的变化。方法采用免疫组化SP法和荧光定量PCR方法检测49例三阴乳腺癌患者新辅助化疗(TA方案)前后乳腺癌组织BCSG1的表达情况,比较化疗前后肿瘤体积的变化,分析新辅助化疗前后BCSG1蛋白表达与肿瘤大小的关系。结果 43例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小,病灶缓解率(CR+PR)为87.8%;新辅助化疗后BCSG1mRNA表达水平亦明显低于化疗前蛋白表达(P<0.05)。新辅助化疗后BCSG1蛋白表达率低于新辅助化疗前蛋白表达(P<0.01)。结论 BCSG1分子和蛋白水平在三阴乳腺癌新辅助化疗后均明显降低,与新辅助化疗后疗效呈负相关(r=0.704,P=0.000),提示BCSG1可作为三阴乳腺癌新辅助化疗疗效的预测因子。
Objective To observe the changes of molecular and protein levels of breast cancer-specific gene BCSG1 before and after neoadjuvant chemotherapy for triple-negative breast cancer. Methods The expression of BCSG1 in breast cancer tissues before and after neoadjuvant chemotherapy (TA regimen) was detected by immunohistochemical SP method and fluorescent quantitative PCR method. The changes of tumor volume before and after chemotherapy were compared. The changes of BCSG1 Relationship between protein expression and tumor size. Results The tumor volume of neoadjuvant chemotherapy in 43 patients with breast cancer was significantly reduced, and the CR + PR was 87.8%. The expression of BCSG1 mRNA in neoadjuvant chemotherapy was also significantly lower than that before chemotherapy (P <0.05). The expression of BCSG1 protein after neoadjuvant chemotherapy was lower than that before neoadjuvant chemotherapy (P <0.01). Conclusions Both BCSG1 and BCSG1 protein levels are significantly decreased after neoadjuvant chemotherapy in patients with triple negative breast cancer (r = 0.704, P = 0.000), suggesting that BCSG1 may be used as a neoadjuvant chemotherapy for triple-negative breast cancer Of predictors.